CPH Stock Overview
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Creso Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.02 |
| 52 Week High | AU$0.099 |
| 52 Week Low | AU$0.018 |
| Beta | 2.69 |
| 1 Month Change | 0% |
| 3 Month Change | -31.03% |
| 1 Year Change | -76.47% |
| 3 Year Change | -86.67% |
| 5 Year Change | -97.81% |
| Change since IPO | -92.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPH | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -9.1% | -4.6% | -0.3% |
| 1Y | -76.5% | -30.2% | 2.4% |
Return vs Industry: CPH underperformed the Australian Pharmaceuticals industry which returned -30.2% over the past year.
Return vs Market: CPH underperformed the Australian Market which returned 2.4% over the past year.
Price Volatility
| CPH volatility | |
|---|---|
| CPH Average Weekly Movement | 14.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CPH is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CPH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Will Lay | https://www.cresopharma.com |
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils.
Creso Pharma Limited Fundamentals Summary
| CPH fundamental statistics | |
|---|---|
| Market Cap | AU$41.14m |
| Earnings (TTM) | -AU$18.15m |
| Revenue (TTM) | AU$7.53m |
5.2x
P/S Ratio-2.2x
P/E RatioIs CPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPH income statement (TTM) | |
|---|---|
| Revenue | AU$7.53m |
| Cost of Revenue | AU$6.10m |
| Gross Profit | AU$1.43m |
| Other Expenses | AU$19.58m |
| Earnings | -AU$18.15m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0093 |
| Gross Margin | 18.95% |
| Net Profit Margin | -241.13% |
| Debt/Equity Ratio | 0% |
How did CPH perform over the long term?
See historical performance and comparison